Chronic wounds affect ~100 million patients worldwide, inflicting significant pain and costing health systems around the world billions. Yet, despite the immense public health burden, innovative treatments for non-healing chronic wounds remain limited.
In 2022, the FDA highlighted the critical need for new product development to address these unmet medical needs. The agency outlined strategies to improve clinical trials, support data sharing, and foster innovation, with the goal of enhancing patient outcomes. Read the full article here ➡️ https://shorturl.at/33qJS
Yet still, healing rates remain largely unchanged, and current gold-standard methods of debridement (a prerequisite for healing) such as surgery, continue to fall short of being effective for most patients.
The prevailing mindset in the industry has been focused on ‘managing’ wounds rather than treating them. The low-risk, low-cost 510(k) pathway has contributed to incremental rather than breakthrough advancements. But there is a growing call from patients, practitioners and regulators for scalable, evidence-backed innovations that move beyond wound care to effective wound therapy.
SolasCure is powering this shift from ‘wound ‘care’ to ‘therapy’ with Aurase Wound Gel, an enzymatic debrider that can be used in all wound treatment settings, aiming to deliver better outcomes and lower costs for patients and healthcare systems.
To learn more about our work and Aurase Wound Gel, visit our website ➡️ https://shorturl.at/OxRn7
#WoundTherapy #WoundCare #WoundResearch
